- Home
- BLK vs GILD Comparison
BLK vs GILD Comparison
Compare BLK & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLK
- GILD
- Stock Information
- Founded
- BLK 1988
- GILD 1987
- Country
- BLK United States
- GILD United States
- Employees
- BLK N/A
- GILD N/A
- Industry
- BLK Investment Bankers/Brokers/Service
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLK Finance
- GILD Health Care
- Exchange
- BLK Nasdaq
- GILD Nasdaq
- Market Cap
- BLK 153.9B
- GILD 140.8B
- IPO Year
- BLK 1999
- GILD 1992
- Fundamental
- Price
- BLK $1,127.77
- GILD $118.96
- Analyst Decision
- BLK Strong Buy
- GILD Buy
- Analyst Count
- BLK 14
- GILD 24
- Target Price
- BLK $1,147.71
- GILD $114.26
- AVG Volume (30 Days)
- BLK 668.9K
- GILD 6.0M
- Earning Date
- BLK 07-15-2025
- GILD 08-07-2025
- Dividend Yield
- BLK 1.85%
- GILD 2.65%
- EPS Growth
- BLK 2.62
- GILD 496.80
- EPS
- BLK 41.34
- GILD 5.01
- Revenue
- BLK $21,573,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- BLK $16.03
- GILD $1.91
- Revenue Next Year
- BLK $0.26
- GILD $3.75
- P/E Ratio
- BLK $27.21
- GILD $23.83
- Revenue Growth
- BLK 15.45
- GILD 3.81
- 52 Week Low
- BLK $773.74
- GILD $72.43
- 52 Week High
- BLK $1,131.93
- GILD $121.38
- Technical
- Relative Strength Index (RSI)
- BLK 61.32
- GILD 63.45
- Support Level
- BLK $1,077.20
- GILD $108.54
- Resistance Level
- BLK $1,131.93
- GILD $121.38
- Average True Range (ATR)
- BLK 16.17
- GILD 2.59
- MACD
- BLK -2.50
- GILD 0.46
- Stochastic Oscillator
- BLK 91.34
- GILD 84.81
About BLK BlackRock Inc.
BlackRock is the largest asset manager in the world, with $11.584 trillion in assets under management at the end of March 2025. Its product mix is diverse, with 53% of managed assets in equity strategies, 26% in fixed income, 9% in multi-asset classes, 8% in money market funds, and 4% in alternatives. Passive strategies account for two thirds of long-term AUM, with the company's ETF platform maintaining a leading market share domestically and on a global basis. Product distribution is weighted more toward institutional clients, which by our calculations account for around 80% of AUM. BlackRock is geographically diverse, with clients in more than 100 countries and more than one third of managed assets coming from investors domiciled outside the US and Canada.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).